RxDoctor Payments Data

Brandy Anderson

Family · Bloomington, INNPI 1487221859

Payments from drug & device makers

$786in general payments, 2019–2025

Across 45 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$247
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$247
  • Novo Nordisk$201
  • Exact Sciences$32
  • Lilly USA, LLC$28
  • Ironshore Pharmaceuticals Inc.$17
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$786100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$786 in reported general payments places this provider in the 60th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$250,903
Medicare patients
218
Services billed
3,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$92,906
IngrezzaValbenazine Tosylate22$82,608
EliquisApixaban260$78,821
JardianceEmpagliflozin251$77,930
OzempicSemaglutide45$46,378
Invega SustennaPaliperidone Palmitate14$34,573
TrulicityDulaglutide36$25,979
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog146$25,184
NamzaricMemantine Hcl/Donepezil Hcl58$17,025
XareltoRivaroxaban34$9,737
Potassium Chloride212$8,445
Divalproex Sodium74$8,074
RexultiBrexpiprazole12$7,750
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen292$7,720
Atorvastatin Calcium367$5,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp$201$50,40258 claims
Lilly USA, LLCTrulicity, Olanzapine$28$28,45993 claims
AbbVieNamzaric$247$17,02558 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,392 family providers in Indiana.

Other family in Bloomington

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →